Investors continue to be pleased with the progress of Oxygen Biotherapeutics Inc.’s newly acquired cardiovascular drug, levosimendan, sending shares of the Morrisville, N.C.-based firm up more than 20 percent Monday on news that the protocol for the planned Phase III study of the calcium sensitizer had been published on Clinicaltrials.gov.